Publication details

Kariprazin v léčbě schizofrenie

Title in English Cariprazine in the treatment of schizophrenia
Authors

ČEŠKOVÁ Eva

Year of publication 2021
Type Article in Periodical
Magazine / Source Psychiatrie pro praxi
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.psychiatriepropraxi.cz/artkey/psy-202102-0006_kariprazin_v_lecbe_schizofrenie.php
Doi http://dx.doi.org/10.36290/psy.2021.019
Keywords third-generation antipsychotic; cariprazine; schizophrenia; efficacy; tolerability
Description Cariprazine is besides aripiprazole the second partial dopamine agonist antipsychotic registered in Czech Republic for the treatment of schizophrenia. Partial dopamine receptor agonists represent the third-generation antipsychotic prototype. Cariprazine peculiar pharmacological profile may explain its efficacy on positive and negative symptoms of schizophrenia. According to the recently published algorithm cariprazine should be used as first-line treatment for patients with predominant negative symptoms. Cariprazine displays a low metabolic risk and weight gain. Among the most reported adverse events are included extrapyramidal symptoms and akathisia; however, they are usually mild, not leading in most cases to treatment interruption.

You are running an old browser version. We recommend updating your browser to its latest version.

More info